Eurand, Inc. company, a subsidiary of Netherlands-based Eurand N.V., develops drug delivery technologies to help drugmakers improve the efficacy of their products. Eurand researches and manufactures drugs marketed in the Americas and Europe, mostly through partnerships with other pharma companies. Eurand's drug delivery systems include Biorise to make certain drugs water soluble; Diffucaps and Minitabs to control the release of drug components as they make their way through the digestive system; and AdvaTab and Liquitard to mask the taste of medicines. The company also conducts research for its parent's own portfolio of drugs under development.

CombiMatrix Corporation company was founded in 1995 and is based in Mukilteo, Washington. CombiMatrix Corporation, together with its subsidiaries, develops technologies, products, and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology, defense, and homeland security. Its technologies include a platform to produce user-defined, in-situ synthesized, and oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations, and proteins in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences, and nanotechnology.CombiMatrix Corporation's products and services include CustomArray platform, an oligonucleotide array for genetic studies; CatalogArray Microarrays for gene expression studies, mutation analysis, and other studies; Micro-RNA Arrays that are used to study micro-RNA molecules; DNA Array Synthesizer, an instrument that enables researchers to fabricate DNA arrays to their specifications; stripping reagents, which enable researchers to re-use microarrays; ElectraSense Reader, an electrochemical scanning instrument; and comparative genomic hybridization arrays, which are used for research and molecular diagnostic applications. CombiMatrix Corporation also offers proprietary molecular synthesis and screening methods for the discovery of potential new drugs. In addition, the company develops capabilities of producing arrays that utilize bacterial artificial chromosomes that enable genetic analysis; and a series of compounds to address various oncology-related diseases. It sells its products and services directly, with partners, and through distributors to customers in the United States, Europe, and Asia.

Experimental and Applied Sciences (EAS) makes and distributes dietary supplements and weight-management products worldwide. The firm's shakes, nutrition bars, protein drinks, and nutritional supplements -- branded as AdvantEdge, Catapult, EAS, Muscle Armor, and Myoplex -- fuel dieters, body builders, and other athletes. EAS also sells training and exercise videos as well as best-selling book, Body for Life (written by one-time owner Bill Phillips). EAS is part of Abbott Nutrition, a division of leading health care products maker Abbott Laboratories.

Compugen Ltd. company was founded in 1993 and is based in Tel Aviv, Israel. Compugen Ltd. (Compugen) is engaged in drug and diagnostic product candidate discovery and the commercialization of such candidates through early-stage licensing and co-development agreements. The Company’s business is focused on developing and using predictive computer-based discovery platforms to discover therapeutic drug candidates and diagnostic biomarker candidates. The Company uses experimental biological processes to validate product candidates discovered by its predictive platforms. Its initial discovery platforms focused mainly on cancer, cardiovascular and immune-related diseases. In July 2008, Compugen announced results from an in vivo study of CGEN-25007, a peptide antagonist of the gp96 protein. The data indicate that CGEN-25007 has immunosuppressive effects and therapeutic potential for the treatment of various inflammatory diseases and other immune related pathologies.

Ondine Biopharma wants to offer an alternative to antibiotics for treating infections. The company is focused on the development and commercialization of its patented light-activated technology, called photodynamic disinfection, as a therapy for bacterial, fungal, and viral infections. Ondine Biopharma is developing a nasal system called MRSAid that incorporates hardware and photosensitizers to help treat often deadly hospital-acquired pathogens, such as staph infections. If commercialized, that product would give the company entry into the hospital infection control market.

Eisai Inc. develops and markets pharmaceuticals to treat a variety of ills. As the US pharmaceutical production arm of Eisai Co., its current product roster includes Alzheimer's treatment Aricept, Aciphex for acid reflux, anticoagulant Fragmin, and anti-convulsant Zonegran. It also maintains an extensive pipeline of potential drugs to address cancer, epilepsy, and severe infection. Subsidiaries Eisai Research Institute of Boston and Eisai Medical Research conduct drug development efforts in areas including oncology, neurology, and gastrointestinal ailments.

New Brunswick Scientific Co. was founded in 1946 and is headquartered in Edison, New Jersey. As of September 24, 2007, New Brunswick Scientific Co. Inc. is a subsidiary of Eppendorf AG. New Brunswick Scientific Co., Inc. and its subsidiaries provide various research equipment and scientific instruments for the life sciences industry. It engages in the design, manufacture, and marketing of equipment that creates, maintains, measures, and controls the physical and biochemical conditions required for the growth, detection, and storage of biological cultures. The company’s products include fermentation equipment, bioreactors, biological shakers, ultra-low temperature freezers, CO2 incubators, nutrient sterilizing and dispensing equipment, tissue culture apparatus, and air samplers. Its products are used in medical, biological, chemical, and environmental research; and for the commercial development of antibiotics, proteins, hormones, enzymes, monoclonal antibodies, agricultural products, fuels, vitamins, vaccines, and other substances. The company sells its equipment to biotechnology and pharmaceutical companies; agricultural and chemical companies; other industrial customers engaged in biotechnology; and medical schools, universities, research institutes, hospitals, and private laboratories; and laboratories of federal, state, and municipal government departments and agencies. It also sells its equipment directly, as well as through scientific equipment dealers to foreign companies, institutions, and governments. The company primarily operates in the United States, Asia, and Europe.

Vion Pharmaceuticals was founded in 1992 and is based in New Haven, Connecticut. On December 17, 2009, Vion Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Vion Pharmaceuticals, Inc., a development-stage pharmaceutical company, develops and commercializes therapeutics for the treatment of cancer. It has two agents in clinical trials, Onrigin and Triapine. Onrigin, a novel alkylating agent that damages DNA to prevent cancer cells from reproducing, is in various clinical trials for the treatment of various indications, such as acute myeloid leukemia (AML), relapsed AML, de novo poor-risk, small cell lung cancer, brain tumors, myelodysplastic syndromes, chronic lymphocytic leukemia, hematologic malignancies, and solid tumors. Triapine is a small molecule in various clinical trials to prevent the replication of tumor cells by blocking a critical step in DNA synthesis. Vion company's other products and product candidates include MELASYN, a water-soluble, synthetic version of melanin for formulation of skin care products and cosmetics; and Nucleoside Analogs, known as elvucitabine, which is in Phase II clinical trials as an antiviral drug for the treatment of human immunodeficiency virus.

OSI Pharmaceuticals, Inc. company was founded in 1983 and is based in Melville, New York. OSI Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of molecular targeted therapies for the treatment of unmet medical needs in oncology, diabetes, and obesity. Its flagship product, Tarceva is a small molecule therapeutic designed to inhibit the receptor tyrosine kinase activity of the protein product of the HER1/EGFR gene. The company also offers Novantrone, a mitoxantrone for injection concentrate. OSI Pharmaceuticals products in Phase I clinical trials include OSI-906, an oral small molecule IGF-1R inhibitor for various cancers, including NSCLC, breast, pancreatic, prostate, colorectal, adrenocortical, and ovarian; PSN821, an oral small molecule drug with anti-diabetic and appetite suppressing effects developed for the treatment of type 2 diabetes; PSN602, a novel dual serotonin and noradrenaline reuptake inhibitor for the long-term treatment of obesity; and OSI-027, a small molecule TORC1/TORC2 inhibitor to supersede first generation mTOR inhibitors. The companys other development programs include OSI-296, a novel potent TKI developed to block compensatory signaling in epithelial tumor cells; OSI-930, a multi-targeted tyrosine kinase inhibitor that acts as a potent co-inhibitor of the receptor tyrosine kinases c-kit and the vascular endothelial growth factor receptor-2; OSI-632, an anti-angiogenesis agent; and CP-868,596, a PDGFR inhibitor. OSI Pharmaceuticals has collaboration agreements with Genentech, Inc.; Roche; and AVEO Pharmaceuticals, Inc.

The Whitehead Institute for Biomedical Research blazes new trails in bioscience. The organization, funded by both the public and private sectors, investigates such diseases as Parkinson's and cancer and dives into the depths of biology, genomics, and genetics to gain new understanding about disease and health. The Whitehead Institute contributed to the international effort to map the human genome, and is actively researching stem cells. Other achievements include discovering a system for multiplying adult stem cells and creating the first genetically defined human cancer cell. The institute was founded in 1982 by philanthropist Edwin "Jack" Whitehead and draws researchers from MIT.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.